TuisHPX • FRA
add
Hisamitsu Pharmaceutical Co Inc
Vorige sluiting
€25,60
Dagwisseling
€25,80 - €25,80
Jaarwisseling
€21,00 - €28,80
Markkapitalisasie
364,25 mjd JPY
Gemiddelde volume
6,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
TYO
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(JPY) | Aug. 2024info | J/J-verandering |
---|---|---|
Inkomste | 39,65 mjd | 13,66% |
Bedryfskoste | 18,75 mjd | 17,95% |
Netto inkomste | 4,31 mjd | -1,33% |
Netto winsgrens | 10,87 | -13,18% |
Wins per aandeel | — | — |
EBITDA | 6,35 mjd | 20,49% |
Effektiewe belastingkoers | 28,38% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(JPY) | Aug. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 122,74 mjd | -13,22% |
Totale bates | 350,48 mjd | 1,79% |
Totale aanspreeklikheid | 74,55 mjd | 7,74% |
Totale ekwiteit | 275,92 mjd | — |
Uitstaande aandele | 73,34 m | — |
Prys om te bespreek | 0,01 | — |
Opbrengs op bates | 3,52% | — |
Opbrengs op kapitaal | 4,46% | — |
Kontantvloei
Netto kontantverandering
(JPY) | Aug. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | 4,31 mjd | -1,33% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
The Hisamitsu Pharmaceutical Co., Inc., headquartered in Saga and Tokyo, is a Japanese multinational pharmaceutical corporation that develops and markets prescription and over-the-counter drug products, especially external pain relieving products such as the transdermal patch. Hisamitsu has specialised in transdermal drug delivery system technology since the introduction of its original line of patches in 1903.
Hisamitsu's products under the Salonpas and Bye-Bye Fever brands are exported to over fifty countries. Hisamitsu also manufactures the Mohrus and Mohrus-Tape lines of external pain relief prescription products for the Japanese drug market. The company also manufactures internal medicines, eyedrops for general application, and the Lifecella Face Mask, a skincare product. Hisamitsu has developed the only over-the-counter transdermal patches approved by the U.S Food and Drug Administration. Wikipedia
Gestig
1847
Hoofkwartier
Webwerf
Werknemers
2 759